We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Test for Rupture of Fetal Membranes

By HospiMedica staff writers
Posted on 03 Oct 2005
A new test for the rupture of fetal membranes (ROM) in pregnant women is noninvasive and has been found to be reliable.

The results of a study in the July 2005 issue of the American Journal of Perinatology showed that the test demonstrated a sensitivity of 98.9%, a specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 99.1%. More...
Called Amni-Sure, the test is the first ROM immunoassay to be approved by the U.S. Food and Drug Administration (FDA). The test was developed by Sepal Reproductive Devices (Sudbury, MA, USA).

The Amni-Sure test detects placental alpha microglobulin-1 (PAMG-1), a protein abundant in amniotic fluid. The test involves collecting a sample with a sterile swab inserted only two-three inches into the vagina for one minute, then placing the swab into a vial with a solvent for one minute, followed by dipping an Amni-Sure test strip into the vial. The test result is indicated visually over the next five-10 minutes by the presence of one or two lines.

The test eliminates the need for nitrazine, ferning, and a speculum examination, and is highly specific: semen, urine, and vaginal infections do not interfere with the results of the test. Sepal Reproductive Devices supplies a full range of devices for assisted reproductive technologies as well as advances in diagnostic testing devices that promote the health of women.






Related Links:
Sepal Reproductive Devices

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical Dressing
ALLEVYN Ag+ SURGICAL
New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.